A Phase 1 interventional study of Digoxin and Furosemide in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this trial is to investigate the relative bioavailabilities of digoxin, furosemide, metformin and rosuvastatin given as a cocktail alone and as a cocktail together with the following drug transporter inhibitors:
Part 1: verapamil (P-gp) and rifampin (OATP1B1/1B3) Part 2: cimetidine (OCT2/MATE) Part 3: probenecid (OAT1/3) The secondary objective is to investigate other potential changes in pharmacokinetics (e.g. in clearance, volume of distribution, etc.) of digoxin, furosemide, metformin and rosuvastatin given as a cocktail alone and as a cocktail together with the inhibitors describe above.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Digoxin · Drug: Furosemide · Drug: Metformin · Drug: Rosuvastatin
Drug: Metformin
Drug: Furosemide
Drug: Digoxin · Drug: Furosemide · Drug: Metformin · Drug: Rosuvastatin · Drug: Verapamil
Drug: Digoxin · Drug: Furosemide · Drug: Metformin · Drug: Rosuvastatin · Drug: Rifampin
Drug: Digoxin · Drug: Furosemide · Drug: Metformin · Drug: Rosuvastatin · Drug: Cimetidine
Drug: Digoxin · Drug: Furosemide · Drug: Metformin · Drug: Rosuvastatin · Drug: Probenecid
Drug: Metformin · Drug: Cimetidine
Drug: Furosemide · Drug: Probenecid
Tablet
Oral solution
Oral solution
Film-coated tablet
Film-coated tablet
Film-coated tablet
Tablet
Tablet
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Verapamil + R1 (T1) vs. R1)
AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. Geometric mean (gMean) presented here is an adjusted gMean and standard error (SE) presented is a geometric SE (gSE).
Time frame: Samples were taken within 0:20 hour:minutes (hh:mm) prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Rifampin + R1 (T2) vs. R1)
AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Cimetidine + R1 (T3) vs. R1)
AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Probenecid + R1 (T4) vs. R1)
AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T1 vs. R1)
Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T2 vs. R1)
Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T3 vs. R1)
Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T4 vs. R1)
Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T1 vs. R1)
AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T2 vs. R1)
AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T3 vs. R1)
AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T4 vs. R1)
AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE.
Time frame: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.
The trial consisted of 3 parts investigating different drug transporter inhibitors. All parts of the trial were performed in healthy male participants in a randomised, open-label, three-way (Part 1) or four-way (Part 2 and 3) crossover design.
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 4 | 4 | 4 | 5 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 4 | 4 | 3 | 5 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Treatment not received | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 4 | 4 | 3 | 5 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 4 | 4 | 3 | 5 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 4 | 4 | 3 | 5 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 4 | 4 | 3 | 5 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 4 | 4 | 3 | 5 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 4 | 4 | 3 | 5 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 4 | 4 | 3 | 5 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 4 | 3 | 3 | 5 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other than listed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 4 | 3 | 3 | 5 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 4 | 3 | 3 | 4 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 4 | 3 | 3 | 5 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 4 | 3 | 3 | 4 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other than listed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Treatment not received due to ae | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. Geometric mean (gMean) presented here is an adjusted gMean and standard error (SE) presented is a geometric SE (gSE).
| Nanomole*hour/litre (nmol*h/L) | Verapamil + R1 (T1) | Cocktail (R1) |
|---|---|---|
| Digoxin | 13.71 ± 1.10 | 13.61 ± 1.10 |
| Furosemide | 165.80 ± 1.06 | 176.85 ± 1.06 |
| Metformin | 1126.22 ± 1.05 | 1357.34 ± 1.05 |
| Rosuvastatin | 98.98 ± 1.11 | 87.29 ± 1.11 |
AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole*hour/litre (nmol*h/L) | Rifampin + R1 (T2) | Cocktail (R1) |
|---|---|---|
| Digoxin | 17.89 ± 1.10 | 13.61 ± 1.10 |
| Furosemide | 211.82 ± 1.06 | 176.85 ± 1.06 |
| Metformin | 1473.38 ± 1.05 | 1357.34 ± 1.05 |
| Rosuvastatin | 303.81 ± 1.11 | 87.29 ± 1.11 |
AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole*hour/litre (nmol*h/L) | Cimetidine + R1 (T3) | Cocktail (R1) |
|---|---|---|
| Digoxin | 19.03 ± 1.07 | 15.15 ± 1.07 |
| Furosemide | 196.39 ± 1.05 | 194.05 ± 1.05 |
| Metformin | 2006.60 ± 1.06 | 1532.41 ± 1.07 |
| Rosuvastatin | 139.54 ± 1.13 | 129.90 ± 1.13 |
AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole*hour/litre (nmol*h/L) | Probenecid + R1 (T4) | Cocktail (R1) |
|---|---|---|
| Digoxin | 14.44 ± 1.08 | 13.52 ± 1.08 |
| Furosemide | 483.38 ± 1.08 | 177.96 ± 1.07 |
| Metformin | 1331.83 ± 1.08 | 1321.20 ± 1.08 |
| Rosuvastatin | 238.16 ± 1.10 | 106.69 ± 1.10 |
Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole/ litre (nmol/ L) | Verapamil + R1 (T1) | Cocktail (R1) |
|---|---|---|
| Digoxin | 1.42 ± 1.09 | 1.17 ± 1.09 |
| Furosemide | 84.32 ± 1.06 | 88.59 ± 1.06 |
| Metformin | 179.45 ± 1.04 | 223.78 ± 1.04 |
| Rosuvastatin | 7.90 ± 1.14 | 6.84 ± 1.14 |
Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole/ litre (nmol/ L) | Rifampin + R1 (T2) | Cocktail (R1) |
|---|---|---|
| Digoxin | 2.55 ± 1.09 | 1.17 ± 1.09 |
| Furosemide | 119.66 ± 1.06 | 88.59 ± 1.06 |
| Metformin | 251.32 ± 1.04 | 223.78 ± 1.04 |
| Rosuvastatin | 77.00 ± 1.14 | 6.84 ± 1.14 |
Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole/ litre (nmol/ L) | Cimetidine + R1 (T3) | Cocktail (R1) |
|---|---|---|
| Digoxin | 1.65 ± 1.07 | 1.35 ± 1.08 |
| Furosemide | 97.69 ± 1.08 | 93.23 ± 1.08 |
| Metformin | 316.83 ± 1.07 | 258.33 ± 1.08 |
| Rosuvastatin | 13.21 ± 1.15 | 11.30 ± 1.15 |
Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole/ litre (nmol/ L) | Probenecid + R1 (T4) | Cocktail (R1) |
|---|---|---|
| Digoxin | 1.13 ± 1.07 | 1.30 ± 1.07 |
| Furosemide | 110.64 ± 1.07 | 90.00 ± 1.07 |
| Metformin | 246.78 ± 1.12 | 243.49 ± 1.12 |
| Rosuvastatin | 43.29 ± 1.11 | 10.11 ± 1.10 |
AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole*hour/litre (nmol*h/L) | Verapamil + R1 (T1) | Cocktail (R1) |
|---|---|---|
| Furosemide | 176.44 ± 1.06 | 191.29 ± 1.06 |
| Metformin | 1147.23 ± 1.05 | 1365.85 ± 1.05 |
| Rosuvastatin | 116.80 ± 1.10 | 94.14 ± 1.10 |
AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole*hour/litre (nmol*h/L) | Rifampin + R1 (T2) | Cocktail (R1) |
|---|---|---|
| Furosemide | 215.63 ± 1.06 | 191.29 ± 1.06 |
| Metformin | 1482.76 ± 1.05 | 1365.85 ± 1.05 |
| Rosuvastatin | 320.72 ± 1.10 | 94.14 ± 1.10 |
AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole*hour/litre (nmol*h/L) | Cimetidine + R1 (T3) | Cocktail (R1) |
|---|---|---|
| Furosemide | 202.17 ± 1.04 | 200.61 ± 1.05 |
| Metformin | 2023.33 ± 1.06 | 1540.21 ± 1.07 |
| Rosuvastatin | 148.32 ± 1.13 | 139.21 ± 1.13 |
AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE.
| Nanomole*hour/litre (nmol*h/L) | Probenecid + R1 (T4) | Cocktail (R1) |
|---|---|---|
| Furosemide | 489.28 ± 1.07 | 188.11 ± 1.07 |
| Metformin | 1346.62 ± 1.08 | 1330.47 ± 1.07 |
| Rosuvastatin | 244.94 ± 1.10 | 113.78 ± 1.10 |
Collected over From first drug administration until 7 days thereafter in each treatment period, up to 22 days for part 1 and 27 days for part 2 and 3.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cocktail (R1) | 0/42 (0%) | 0/42 (0%) | 5/42 (11.9%) |
| Verapamil + R1 (T1) | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Rifampin + R1 (T2) | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Metformin (R2) | 0/16 (0%) | 0/16 (0%) | 7/16 (43.8%) |
| Cimetidine + R1 (T3) | 0/17 (0%) | 0/17 (0%) | 7/17 (41.2%) |
| Cimetidine + R2 (T5) | 0/17 (0%) | 0/17 (0%) | 7/17 (41.2%) |
| Furosemide (R3) | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Probenecid + R1 (T4) | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Probenecid + R3 (T6) | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) |
| Event | Cocktail (R1) | Verapamil + R1 (T1) | Rifampin + R1 (T2) | Metformin (R2) | Cimetidine + R1 (T3) | Cimetidine + R2 (T5) | Furosemide (R3) | Probenecid + R1 (T4) | Probenecid + R3 (T6) |
|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/42 | 0/12 | 1/12 | 4/16 | 3/17 | 2/17 | 2/16 | 0/16 | 1/15 |
| NauseaGastrointestinal disorders | 0/42 | 0/12 | 0/12 | 1/16 | 1/17 | 2/17 | 0/16 | 1/16 | 1/15 |
| VomitingGastrointestinal disorders | 1/42 | 0/12 | 1/12 | 0/16 | 0/17 | 1/17 | 1/16 | 0/16 | 0/15 |
| NasopharyngitisInfections and infestations | 1/42 | 1/12 | 1/12 | 1/16 | 0/17 | 1/17 | 1/16 | 1/16 | 0/15 |
| Orthostatic intoleranceNervous system disorders | 0/42 | 0/12 | 1/12 | 0/16 | 0/17 | 0/17 | 0/16 | 0/16 | 0/15 |
| VertigoEar and labyrinth disorders | 0/42 | 0/12 | 0/12 | 0/16 | 1/17 | 1/17 | 0/16 | 0/16 | 1/15 |
| MalaiseGeneral disorders | 0/42 | 0/12 | 0/12 | 0/16 | 0/17 | 0/17 | 0/16 | 0/16 | 1/15 |
| Dry eyeEye disorders | 0/42 | 0/12 | 0/12 | 1/16 | 0/17 | 0/17 | 0/16 | 0/16 | 0/15 |
| DiarrhoeaGastrointestinal disorders | 1/42 | 0/12 | 0/12 | 1/16 | 1/17 | 1/17 | 0/16 | 0/16 | 0/15 |
| Influenza like illnessGeneral disorders | 0/42 | 0/12 | 0/12 | 1/16 | 0/17 | 0/17 | 0/16 | 0/16 | 0/15 |
Treated set (TS): All subjects who were dispended study medication and were documented to have taken at least 1 dose of study medication.
| Age, Continuous(Years) | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1 | 30.0 ± 6.8 | 51.5 ± 1.3 | 36.3 ± 10.6 | 32.8 ± 10.2 | 38.3 ± 13.1 | 35.3 ± 11.1 | 41.6 ± 10.5 | 29.3 ± 7.9 | 30.0 ± 8.8 | 33.0 ± 13.2 | 43.5 ± 8.1 | 36.6 ± 10.8 |
| Sex: Female, Male(Participants) | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 45 |
| Ethnicity (NIH/OMB)(Participants) | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 45 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cocktail (R1)/ (Verapamil + R1)/ (Rifampin + R1) | (Verapamil + R1)/ (Rifampin + R1)/ R1 | (Rifampin + R1)/ R1/ (Verapamil + R1) | R1/ Metformin/ (Cimetidine+R1)/ (Cimetidine+Metformin) | Metformin/ (Cimetidine+Metformin)/ R1/ (Cimetidine+R1) | (Cimetidine+R1)/ R1/ (Cimetidine+Metformin)/ Metformin | (Cimetidine+Metformin)/ (Cimetidine+R1)/ Metformin/ R1 | R1/ Furosemide/ (Probenecid + R1)/ (Probenecid + Furosemide) | Furosemide/ (Probenecid + Furosemide)/ R1/ (Probenecid + R1) | (Probenecid + R1)/ R1/ (Probenecid + Furosemide)/ Furosemide | (Probenecid + Furosemide)/ (Probenecid + R1)/ Furosemide/ R1 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 4 | 4 | 4 | 4 | 3 | 5 | 4 | 4 | 4 | 4 | 44 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Oct 2017 to primary completion in May 2018, 6 months.
Results were first posted in Jul 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Digoxin · Furosemide · Metformin · Rosuvastatin · Verapamil · Rifampin · Cimetidine · Probenecid